Skip to main content
Advertisement
Advertisement

ALT

ALT logo

Altimmune, Inc. Common Stock

3.19
USD
Sponsored
-0.22
-6.45%
Sep 23, 15:58 UTC -4
Closed
exchange

After-Market

3.21

+0.02
+0.47%

ALT Earnings Reports

Positive Surprise Ratio

ALT beat 24 of 34 last estimates.

71%

Next Report

Date of Next Report
Nov 04, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/
-$0.13
Implied change from Q2 26 (Revenue/ EPS)
--
/
+8.33%
Implied change from Q3 25 (Revenue/ EPS)
-100.00%
/
-38.10%

Altimmune, Inc. Common Stock earnings per share and revenue

On Aug 12, 2026, ALT reported earnings of -0.12 USD per share (EPS) for Q2 26, beating the estimate of -0.13 USD, resulting in a 14.22% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -2.33% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 9 analysts forecast an EPS of -0.13 USD, with revenue projected to reach -- USD, implying an increase of 8.33% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Champions Oncology, Inc.
Report Date
Sep 10, 2026 For Q1 27
Estimate
-$0.01
Actual
-$0.03
Surprise
-194.12%
logo
PharmaCyte Biotech, Inc. Common Stock
Report Date
Sep 14, 2026 For Q1 27
Estimate
-
Actual
-$0.54
Surprise
-
FAQ
For Q2 2026, Altimmune, Inc. Common Stock reported EPS of -$0.12, beating estimates by 14.22%, and revenue of $0.00, 0% as expectations.
The stock price moved down -2.33%, changed from $3.00 before the earnings release to $2.93 the day after.
The next earning report is scheduled for Nov 04, 2026.
Based on 9 analysts, Altimmune, Inc. Common Stock is expected to report EPS of -$0.13 and revenue of -- for Q3 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement